You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Patient diagnostic evaluation data (n = 28)

From: Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study

Characteristic No. of patients (%)
Endoscopy and histologic features
 Type of endoscopy
  Colonoscopy 22 (79)
  Flexible sigmoidoscopy 6 (21)
 Endoscopic findings on initial evaluation
  Ulceration 8 (29)
  Nonulcerative inflammation 13 (46)
  Normal 7 (25)
 Endoscopic distribution
  Extensive 14 (50)
  Left colon only 5 (18)
  Isolated small bowel 2 (7)
 Histological inflammation on initial evaluation
  Active features 28 (100)
  Chronic features 14 (50)
  Microscopic 10 (36)
  Median no. of endoscopic procedures (IQR) 2 (1–7)
 Diagnostic laboratory studies
  Mean duration of laboratory follow-up, months (SD) 3 (4)
  Positive fecal lactoferrin at onset of diarrheaa 23 (100)
  Positive fecal lactoferrin after vedolizumab therapyb 11 (79)
  Mean fecal calprotectin value at onset of diarrhea μg/g (SD)c 329 (276)
Mean fecal calprotectin value at follow-up μg/g (SD)d 218 (262)
  1. Abbreviations: IQR, interquartile range; SD, standard deviation.
  2. aLactoferrin was initially measured for 23 patients
  3. bLactoferrin was measured at follow-up for 14 patients
  4. cCalprotectin was initially measured for 19 patients
  5. dCalprotectin was measured at follow-up for 13 patients